MedTrace Logo

Libyan Multiple Sclerosis Registry Study

NCT07264725 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 369

Last updated 2025-12-04

No results posted yet for this study

Summary

This study aims to understand differences in access to diagnosis and treatment for people with multiple sclerosis (MS) receiving care in Libya. The study uses data from the Libyan Multiple Sclerosis Registry, which collects clinical and treatment information from patients at two tertiary neurology centres. The main focus is to examine how long it takes for patients to receive an MS diagnosis, who has access to high-efficacy disease-modifying therapies, and how these factors relate to disability levels. The results will help identify gaps in MS care within a conflict-affected health system and guide improvements in services for patients in Libya.

Conditions

Interventions

DRUG

Disease-Modifying Therapies

This is an observational study. No medications are assigned, administered, or modified by the study team. Disease-modifying therapies (DMTs) are recorded only as exposure variables based on routine clinical care. All drugs listed in this record are prescribed independently by treating neurologists as part of standard care, and the study does not influence treatment decisions in any way.

Sponsors & Collaborators

  • University of Zintan

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-02
Primary Completion
2025-04-30
Completion
2025-04-30

Countries

  • Libya

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07264725 on ClinicalTrials.gov